723 related articles for article (PubMed ID: 31096005)
21. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.
Hussar DA; Kavelak HL
J Am Pharm Assoc (2003); 2015; 55(2):216, 219-20, 222. PubMed ID: 25749267
[No Abstract] [Full Text] [Related]
22. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
23. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Belperio PS; Shahoumian TA; Loomis TP; Backus LI
J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
[TBL] [Abstract][Full Text] [Related]
24. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Cheng EY; Saab S; Holt CD; Busuttil RW
Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
[TBL] [Abstract][Full Text] [Related]
25. Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
Turgeon MK; Shah SA; Delman AM; Tran BV; Agopian VG; Wedd JP; Magliocca JF; Kim A; Cameron A; Olyaei A; Orloff SL; Anderson MP; Kubal CA; Cannon RM; Locke JE; Simpson MA; Akoad ME; Wongjirad CP; Emamaullee J; Moro A; Aucejo F; Feizpour CA; Vagefi PA; Nguyen MH; Esquivel CO; Dhanireddy K; Subramanian V; Chavarriaga A; Kazimi MM; Anderson MS; Sonnenday CJ; Kim SC; Foley DP; Abdouljoud M; Salgia RJ; Moris D; Sudan DL; Ganesh SR; Humar A; Doyle M; Chapman WC; Maithel SK
Ann Surg; 2021 Oct; 274(4):613-620. PubMed ID: 34506316
[TBL] [Abstract][Full Text] [Related]
26. Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
Ferreira VL; Leonart LP; Tonin FS; Borba HHL; Pontarolo R
Clin Drug Investig; 2018 May; 38(5):389-400. PubMed ID: 29435907
[TBL] [Abstract][Full Text] [Related]
27. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
28. Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.
Mantry PS; Pathak L
Expert Rev Anti Infect Ther; 2016; 14(2):157-65. PubMed ID: 26567871
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
Beste LA; Green PK; Berry K; Kogut MJ; Allison SK; Ioannou GN
J Hepatol; 2017 Jul; 67(1):32-39. PubMed ID: 28267622
[TBL] [Abstract][Full Text] [Related]
30. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.
Poordad F; Agarwal K; Younes Z; Cohen D; Xie W; Podsadecki T
Clin Infect Dis; 2015 Feb; 60(4):608-10. PubMed ID: 25365973
[TBL] [Abstract][Full Text] [Related]
31. Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Krastev Z; Jelev D; Antonov K; Petkova T; Atanasova E; Zheleva N; Tomov B; Boyanova Y; Mateva L
World J Gastroenterol; 2016 Feb; 22(8):2630-5. PubMed ID: 26937151
[TBL] [Abstract][Full Text] [Related]
32. Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
Weil C; Mehta D; Koren G; Pinsky B; Samp JC; Chodick G; Shalev V
J Viral Hepat; 2018 Feb; 25(2):144-151. PubMed ID: 28984012
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
Aliment Pharmacol Ther; 2018 Jul; 48(1):35-43. PubMed ID: 29797514
[TBL] [Abstract][Full Text] [Related]
35. Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.
Jung J; Kwon JH; Song GW; Tak EY; Kirchner VA; Lee SG
J Gastrointest Surg; 2018 Aug; 22(8):1334-1342. PubMed ID: 29679347
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.
Wu J; Huang P; Fan H; Tian T; Xia X; Fu Z; Wang Y; Ye X; Yue M; Zhang Y
Virol J; 2019 Jan; 16(1):11. PubMed ID: 30654809
[TBL] [Abstract][Full Text] [Related]
37. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Steiner S; Bucsics T; Schwabl P; Mandorfer M; Scheiner B; Aichelburg MC; Grabmeier-Pfistershammer K; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
Wien Klin Wochenschr; 2017 Aug; 129(15-16):517-526. PubMed ID: 28130599
[TBL] [Abstract][Full Text] [Related]
38. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
Örmeci N; Gülşen MT; Sezgin O; Aghayeva S; Demir M; Köksal I; Güner R; Erarslan E; Asiller ÖÖ; Balkan A; Yaraş S; Çalışkan Kartal A
Turk J Gastroenterol; 2020 Feb; 31(2):148-155. PubMed ID: 32141824
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C.
Garcia-Pajares F; Tejedor-Tejada J; Torres-Yuste R; Almohalla-Alvárez C; Sánchez-Ocaña R; Peñas-Herrero I; Cimavilla-Román M; de Benito-Sanz M; Sánchez-Martín F; Sánchez-Antolín G
Transplant Proc; 2019; 51(1):74-76. PubMed ID: 30655151
[TBL] [Abstract][Full Text] [Related]
40. First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
Yesmembetov K; Ashimkhanova A; Kaliaskarova K
Exp Clin Transplant; 2016 Nov; 14(Suppl 3):112-113. PubMed ID: 27805527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
